The challenge of HIV-1 subtype diversity.
作者信息
Taylor Barbara S, Sobieszczyk Magdalena E, McCutchan Francine E, Hammer Scott M
机构信息
Department of Medicine and the Division of Infectious Diseases, Columbia University Medical Center, New York 10032, USA.
出版信息
N Engl J Med. 2008 Apr 10;358(15):1590-602. doi: 10.1056/NEJMra0706737.
Abstract
摘要
相似文献
1
The challenge of HIV-1 subtype diversity.
N Engl J Med. 2008 Apr 10;358(15):1590-602. doi: 10.1056/NEJMra0706737.
2
Impact of HIV-1 pol diversity on drug resistance and its clinical implications.
Curr Opin Infect Dis. 2006 Dec;19(6):594-606. doi: 10.1097/QCO.0b013e3280109122.
3
Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
J Clin Virol. 2017 Oct;95:13-19. doi: 10.1016/j.jcv.2017.07.013. Epub 2017 Jul 25.
4
Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa.
J Infect Dis. 2006 Sep 15;194 Suppl 1:S45-50. doi: 10.1086/505353.
5
When do minority drug-resistant HIV-1 variants have a major clinical impact?
J Infect Dis. 2010 Mar;201(5):647-9. doi: 10.1086/650545.
6
[Evolution and Diversity of HIV-1].
Praxis (Bern 1994). 2011 Jan 5;100(1):29-35. doi: 10.1024/1661-8157/a000403.
7
The genetic variability of HIV-1 and its implications.
Transfus Clin Biol. 2001 Jun;8(3):222-5. doi: 10.1016/s1246-7820(01)00131-8.
8
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404.
9
The clades of HIV: their origins and clinical significance.
AIDS Rev. 2003 Oct-Dec;5(4):205-13.
10
引用本文的文献
1
Effective primer design for genotype and subtype detection of highly divergent viruses in large scale genome datasets.
BMC Bioinformatics. 2025 Sep 1;26(1):223. doi: 10.1186/s12859-025-06251-9.
2
Evidence for circulation of high-virulence HIV-1 subtype B variants in the United Kingdom.
Virus Evol. 2025 May 20;11(1):veaf048. doi: 10.1093/ve/veaf048. eCollection 2025.
3
Integrated Immuno and bioinformatics assisted novel epitope vaccine against HIV infection: a study based on complete genome.
Virol J. 2025 Jul 9;22(1):228. doi: 10.1186/s12985-025-02764-0.
4
High genetic diversity of HIV-1 pol region and molecular transmission networks among people living with HIV-1 in Haikou, South China, 2005-2022.
BMC Infect Dis. 2025 Jul 1;25(1):813. doi: 10.1186/s12879-025-11184-y.
5
A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
J Virol. 2025 Apr 15;99(4):e0226724. doi: 10.1128/jvi.02267-24. Epub 2025 Mar 27.
6
The synthesis and investigation of novel 3-benzoylbenzofurans and pyrazole derivatives for anti-HIV activity.
RSC Med Chem. 2025 Feb 5;16(5):2142-2158. doi: 10.1039/d4md00844h. eCollection 2025 May 22.
7
Prediction of the Co-receptor usage of the main worldwide HIV-1 subtypes, CRF, and CRF35-AD in Iranian patients via the five genotypic tools.
Biochem Biophys Rep. 2025 Feb 17;41:101939. doi: 10.1016/j.bbrep.2025.101939. eCollection 2025 Mar.
8
Single-cell delineation of strain-specific HIV-1 Vif activities using dual reporter sensor cells and live cell imaging.
J Virol. 2025 Mar 18;99(3):e0157924. doi: 10.1128/jvi.01579-24. Epub 2025 Feb 25.
9
Computer aided design of inhibitor molecules against Vpr protein from different HIV-1 subtypes.
In Silico Pharmacol. 2025 Feb 8;13(1):23. doi: 10.1007/s40203-025-00318-4. eCollection 2025.
10
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
bioRxiv. 2025 Jan 20:2025.01.17.633475. doi: 10.1101/2025.01.17.633475.
本文引用的文献
1
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.
J Infect Dis. 2008 Mar 1;197(5):707-13. doi: 10.1086/527416.
2
AIDS research. Did Merck's failed HIV vaccine cause harm?
Science. 2007 Nov 16;318(5853):1048-9. doi: 10.1126/science.318.5853.1048.
3
Design and pre-clinical evaluation of a universal HIV-1 vaccine.
PLoS One. 2007 Oct 3;2(10):e984. doi: 10.1371/journal.pone.0000984.
4
A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD.
AIDS Res Hum Retroviruses. 2007 Jun;23(6):834-9. doi: 10.1089/aid.2006.0299.
5
An HIV vaccine--evolving concepts.
N Engl J Med. 2007 May 17;356(20):2073-81. doi: 10.1056/NEJMra066267.
6
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
J Virol. 2007 Aug;81(15):7885-93. doi: 10.1128/JVI.00218-07. Epub 2007 May 16.
7
Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.
Infect Genet Evol. 2007 Jun;7(3):391-8. doi: 10.1016/j.meegid.2007.01.009. Epub 2007 Feb 8.
8
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.
J Infect Dis. 2007 Apr 15;195(8):1177-80. doi: 10.1086/512682. Epub 2007 Mar 2.
9
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
AIDS. 2007 Jan 11;21(2):265-6. doi: 10.1097/QAD.0b013e32801199ee.
10
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
J Virol. 2007 Mar;81(5):2359-71. doi: 10.1128/JVI.02006-06. Epub 2006 Dec 20.
Zotero 插件